Related Articles
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non‑small cell lung cancer
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)
High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
Expression of immune checkpoint PD‑1 in non‑small cell lung cancer is associated with tumor cell DNA‑dependent protein kinase